JP2012517818A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012517818A5 JP2012517818A5 JP2011550552A JP2011550552A JP2012517818A5 JP 2012517818 A5 JP2012517818 A5 JP 2012517818A5 JP 2011550552 A JP2011550552 A JP 2011550552A JP 2011550552 A JP2011550552 A JP 2011550552A JP 2012517818 A5 JP2012517818 A5 JP 2012517818A5
- Authority
- JP
- Japan
- Prior art keywords
- variable domain
- single variable
- tnfr1
- seq
- dom7h
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102100003095 TNFRSF1A Human genes 0.000 claims 16
- 101710038526 TNFRSF1A Proteins 0.000 claims 14
- 125000003275 alpha amino acid group Chemical group 0.000 claims 8
- 230000027455 binding Effects 0.000 claims 8
- 102000018358 Immunoglobulins Human genes 0.000 claims 6
- 108060003951 Immunoglobulins Proteins 0.000 claims 6
- 239000003446 ligand Substances 0.000 claims 5
- 102000007562 Serum Albumin Human genes 0.000 claims 4
- 108010071390 Serum Albumin Proteins 0.000 claims 4
- 230000003042 antagnostic Effects 0.000 claims 4
- 239000005557 antagonist Substances 0.000 claims 4
- 230000002401 inhibitory effect Effects 0.000 claims 4
- 241000282567 Macaca fascicularis Species 0.000 claims 3
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 3
- 108010001801 Tumor Necrosis Factor-alpha Proteins 0.000 claims 3
- 238000004166 bioassay Methods 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 241000282465 Canis Species 0.000 claims 2
- 102000004890 Interleukin-8 Human genes 0.000 claims 2
- 108090001007 Interleukin-8 Proteins 0.000 claims 2
- 229920001850 Nucleic acid sequence Polymers 0.000 claims 2
- 230000004968 inflammatory condition Effects 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 102000005962 receptors Human genes 0.000 claims 2
- 108020003175 receptors Proteins 0.000 claims 2
- 230000028327 secretion Effects 0.000 claims 2
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 claims 2
- 206010003246 Arthritis Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 230000035687 Dissociation Rate Constant Effects 0.000 claims 1
- 230000036947 Dissociation constant Effects 0.000 claims 1
- 206010021972 Inflammatory bowel disease Diseases 0.000 claims 1
- 230000003013 cytotoxicity Effects 0.000 claims 1
- 231100000135 cytotoxicity Toxicity 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 230000036963 noncompetitive Effects 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
Claims (15)
- 抗TNFα受容体1型(TNFR1;p55)免疫グロブリン単一可変ドメインであって、DOM1h−574−156(配列番号1)のアミノ酸配列と少なくとも95%同一のアミノ酸配列を含む、単一可変ドメイン。
- 単一可変ドメインが、表面プラズモン共鳴で測定した解離定数(KD)500pM以下でヒトTNFR1に特異的に結合する結合部位を含む、請求項1に記載の単一可変ドメイン。
- 単一可変ドメインが、表面プラズモン共鳴で測定した解離速度定数(Koff)2×10−4s−1以下でヒトTNFR1に特異的に結合する結合部位を含む、請求項1または2に記載の単一可変ドメイン。
- 単一可変ドメインが、ヒト、カニクイザルおよび任意にイヌTNFR1に特異的に結合する、請求項1、2または3に記載の単一可変ドメイン。
- 単一可変ドメインが、ヒト、カニクイザルおよび任意にイヌTNFR1のDOM1h−574−156(配列番号1)への結合を阻害する、請求項1〜4のいずれか1項に記載の単一可変ドメイン。
- 単一可変ドメインが:
i.標準的MRC5アッセイ法においてTNFα誘発性IL−8分泌の阻害により測定したND50約5nM以下でTNFR1を中和する;
ii.標準的L929アッセイ法においてTNFα誘発性細胞毒性の阻害により測定したND50約150nM以下でTNFR1を中和する;
iii.標準的カニクイザルKIアッセイ法においてTNFα誘発性IL−8分泌の阻害により測定したND50約5nM以下でTNFR1を中和する;および/または
iv.TNFR1の非競合阻害剤である、
請求項1〜5のいずれか1項に記載の単一可変ドメイン。 - 請求項1〜6のいずれか1項に記載の免疫グロブリン単一可変ドメインと、任意に、血清アルブミン(SA)に特異的に結合する少なくとも1つの免疫グロブリン単一可変ドメインとを含む、多重特異性リガンド。
- 抗SA単一可変ドメインが、DOM7h−11(配列番号28)、DOM7h−11−3(配列番号29)、DOM7h−11−12(配列番号30)、DOM7h−11−15(配列番号31)、DOM7h−14(配列番号32)、DOM7h−14−10(配列番号33)、DOM7h−14−18(配列番号34)またはDOM7m−16(配列番号35)の配列と少なくとも80%同一のアミノ酸配列を含む、請求項7に記載の多重特異性リガンド。
- リンカーが抗TNFR1単一可変ドメインと抗SA単一可変ドメイン間に提供され、アミノ酸配列AST、任意にASTSGPSを含む、請求項7または8に記載の多重特異性リガンド。
- (i)DOM1h−574−156(配列番号1)のアミノ酸配列と少なくとも95%同一のアミノ酸配列を含む抗TNFα受容体1型(TNFR1;p55)免疫グロブリン単一可変ドメインと、(ii)血清アルブミン(SA)に特異的に結合する少なくとも1つの抗SA免疫グロブリン単一可変ドメインであって、DOM7h−11−3(配列番号29)の配列と少なくとも80%同一のアミノ酸配列を含む抗SA単一可変ドメインと、(iii)任意に、抗TNFR1単一可変ドメインと抗SA単一可変ドメイン間に提供されたリンカーであって、アミノ酸配列AST、任意にASTSGPSを含むリンカーとを含む、多重特異性リガンド。
- 請求項1〜10のいずれか1項に記載の単一可変ドメインまたは多重特異性リガンドを含む、TNFR1アンタゴニスト。
- 炎症状態の治療および/または予防のための、請求項11に記載のTNFR1アンタゴニスト。
- 炎症状態の治療および/または予防のための医薬品の製造における、請求項11に記載のTNFR1アンタゴニストの使用。
- 前記状態が関節炎、多発性硬化症、炎症腸疾患および慢性閉塞性肺疾患からなる群から選択される、請求項12に記載のアンタゴニストまたは請求項13に記載の使用。
- 核酸が、DOM1h−574−156(配列番号1)のヌクレオチド配列と少なくとも80%同一のヌクレオチド配列を含み、核酸が、TNFR1に特異的に結合する免疫グロブリン単一可変ドメインを含むポリペプチドをコードする、単離、または組換え型核酸。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15374609P | 2009-02-19 | 2009-02-19 | |
US61/153,746 | 2009-02-19 | ||
US24119809P | 2009-09-10 | 2009-09-10 | |
US61/241,198 | 2009-09-10 | ||
PCT/EP2010/052005 WO2010094720A2 (en) | 2009-02-19 | 2010-02-17 | Improved anti-tnfr1 polypeptides, antibody variable domains & antagonists |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015151376A Division JP2016007218A (ja) | 2009-02-19 | 2015-07-31 | 改善された抗tnfr1ポリペプチド、抗体可変ドメインおよびアンタゴニスト |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2012517818A JP2012517818A (ja) | 2012-08-09 |
JP2012517818A5 true JP2012517818A5 (ja) | 2013-03-07 |
Family
ID=42136168
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011550552A Pending JP2012517818A (ja) | 2009-02-19 | 2010-02-17 | 改善された抗tnfr1ポリペプチド、抗体可変ドメインおよびアンタゴニスト |
JP2015151376A Pending JP2016007218A (ja) | 2009-02-19 | 2015-07-31 | 改善された抗tnfr1ポリペプチド、抗体可変ドメインおよびアンタゴニスト |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015151376A Pending JP2016007218A (ja) | 2009-02-19 | 2015-07-31 | 改善された抗tnfr1ポリペプチド、抗体可変ドメインおよびアンタゴニスト |
Country Status (14)
Country | Link |
---|---|
US (1) | US20110301335A1 (ja) |
EP (1) | EP2398827A2 (ja) |
JP (2) | JP2012517818A (ja) |
KR (1) | KR20110119806A (ja) |
CN (1) | CN102405236A (ja) |
AU (1) | AU2010215479B2 (ja) |
BR (1) | BRPI1008014A2 (ja) |
CA (1) | CA2750477A1 (ja) |
EA (1) | EA022925B1 (ja) |
IL (1) | IL214648A0 (ja) |
MX (1) | MX2011008799A (ja) |
SG (1) | SG173173A1 (ja) |
WO (1) | WO2010094720A2 (ja) |
ZA (1) | ZA201105627B (ja) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9028822B2 (en) * | 2002-06-28 | 2015-05-12 | Domantis Limited | Antagonists against TNFR1 and methods of use therefor |
EP3656788A3 (en) * | 2009-02-19 | 2020-07-29 | Glaxo Group Limited | Improved anti-serum albumin binding variants |
WO2011008814A2 (en) | 2009-07-14 | 2011-01-20 | Immune Tolerance Institute, Inc., A California Not-For-Profit Corporation | Multiplexed measurement of exogenous and endogenous dna |
CA2768460A1 (en) * | 2009-07-16 | 2011-01-20 | Glaxo Group Limited | Antagonists, uses & methods for partially inhibiting tnfr1 |
TW201125877A (en) * | 2009-10-27 | 2011-08-01 | Glaxo Group Ltd | Stable anti-TNFR1 polypeptides, antibody variable domains & and antagonists |
BR112012029280A2 (pt) | 2010-05-20 | 2016-11-29 | Glaxo Group Ltd | variante de domínio variável único de imunoglobulina antialbumina sérica, imunoglobulina anti-sa, ligando multiespecífico, proteína de fusão, composição, ácido nucleico, vetor, célula hospedeira isolada, e, uso de uma variante, ligando multiespecífico ou proteína de fusão |
US8859739B2 (en) | 2010-09-16 | 2014-10-14 | Baliopharm Ag | Anti-huTNFR1 antibody and methods of use thereof for treatment |
EP2721066A1 (en) * | 2011-06-17 | 2014-04-23 | Glaxo Group Limited | Tumour necrosis factor receptor 1 antagonists |
WO2015104322A1 (en) | 2014-01-09 | 2015-07-16 | Glaxosmithkline Intellectual Property Development Limited | Treatment of inflammatory diseases with non-competitive tnfr1 antagonists |
US9815886B2 (en) | 2014-10-28 | 2017-11-14 | Adma Biologics, Inc. | Compositions and methods for the treatment of immunodeficiency |
WO2016094309A1 (en) * | 2014-12-10 | 2016-06-16 | Myosotis | Inhibition of tnf signaling in cancer immunotherapy |
NO2768984T3 (ja) * | 2015-11-12 | 2018-06-09 | ||
CN107043413A (zh) * | 2016-02-05 | 2017-08-15 | 华中农业大学 | 一种肺结核相关的尿液生物标志蛋白及其应用 |
US10259865B2 (en) | 2017-03-15 | 2019-04-16 | Adma Biologics, Inc. | Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection |
CN113711038A (zh) * | 2019-01-31 | 2021-11-26 | 积水医疗株式会社 | 用于生物样品中游离aim的免疫分析方法及用于检测对象中nash的方法 |
CA3193273A1 (en) | 2020-08-27 | 2022-03-03 | Enosi Therapeutics Corporation | Methods and compositions to treat autoimmune diseases and cancer |
WO2022117569A1 (en) | 2020-12-02 | 2022-06-09 | Oncurious Nv | A ccr8 antagonist antibody in combination with a lymphotoxin beta receptor agonist antibody in therapy against cancer |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
GB8725529D0 (en) | 1987-10-30 | 1987-12-02 | Delta Biotechnology Ltd | Polypeptides |
JP3095168B2 (ja) | 1988-02-05 | 2000-10-03 | エル. モリソン,シェリー | ドメイン‐変性不変部を有する抗体 |
ATE151110T1 (de) | 1988-09-02 | 1997-04-15 | Protein Eng Corp | Herstellung und auswahl von rekombinantproteinen mit verschiedenen bindestellen |
ATE92107T1 (de) | 1989-04-29 | 1993-08-15 | Delta Biotechnology Ltd | N-terminale fragmente von menschliches serumalbumin enthaltenden fusionsproteinen. |
US5977307A (en) | 1989-09-07 | 1999-11-02 | Alkermes, Inc. | Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins |
US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
WO1994026087A2 (en) | 1993-05-14 | 1994-11-24 | Connor Kim C O | Recombinant protein production and insect cell culture and process |
JPH08511420A (ja) | 1993-06-16 | 1996-12-03 | セルテック・セラピューテイクス・リミテッド | 抗 体 |
DE69838521T2 (de) | 1997-07-07 | 2008-05-21 | Medical Research Council | Methode zur Erhöhung der Konzentration von Nucleinsäuremolekülen |
IL127127A0 (en) | 1998-11-18 | 1999-09-22 | Peptor Ltd | Small functional units of antibody heavy chain variable regions |
WO2001058953A2 (en) | 2000-02-11 | 2001-08-16 | The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Identification of a domain in the tumor necrosis factor receptor family that mediates pre-ligand receptor assembly and function |
EP1399484B1 (en) | 2001-06-28 | 2010-08-11 | Domantis Limited | Dual-specific ligand and its use |
AU2003210806A1 (en) | 2002-03-05 | 2003-09-22 | Eli Lilly And Company | Heterologous g-csf fusion proteins |
ATE328906T1 (de) | 2002-06-28 | 2006-06-15 | Domantis Ltd | Dual-specifische liganden mit erhöhter halbwertszeit |
US9321832B2 (en) * | 2002-06-28 | 2016-04-26 | Domantis Limited | Ligand |
US7696320B2 (en) | 2004-08-24 | 2010-04-13 | Domantis Limited | Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor |
US20060002935A1 (en) * | 2002-06-28 | 2006-01-05 | Domantis Limited | Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor |
WO2004041865A2 (en) | 2002-11-08 | 2004-05-21 | Ablynx N.V. | Stabilized single domain antibodies |
GB0230203D0 (en) | 2002-12-27 | 2003-02-05 | Domantis Ltd | Fc fusion |
EP1578801A2 (en) | 2002-12-27 | 2005-09-28 | Domantis Limited | Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand |
WO2004101790A1 (en) | 2003-05-14 | 2004-11-25 | Domantis Limited | A process for recovering polypeptides that unfold reversibly from a polypeptide repertoire |
CA2529819A1 (en) | 2003-06-30 | 2004-09-23 | Domantis Limited | Pegylated single domain antibodies |
PL1729795T3 (pl) | 2004-02-09 | 2016-08-31 | Human Genome Sciences Inc | Białka fuzyjne albuminy |
PT1737962E (pt) | 2004-03-24 | 2010-12-03 | Domantis Ltd | Sequência líder universal gas1 |
GB0418651D0 (en) | 2004-08-20 | 2004-09-22 | Medical Res Council | Method |
CN101084014A (zh) * | 2004-10-08 | 2007-12-05 | 杜门蒂斯有限公司 | 抗肿瘤坏死因子受体1的单域抗体及其使用方法 |
GB0521621D0 (en) | 2005-10-24 | 2005-11-30 | Domantis Ltd | Tumor necrosis factor receptor 1 antagonists for treating respiratory diseases |
AU2006321364B2 (en) * | 2005-12-01 | 2011-11-10 | Domantis Limited | Noncompetitive domain antibody formats that bind Interleukin 1 Receptor type 1 |
KR20080077261A (ko) * | 2005-12-06 | 2008-08-21 | 도만티스 리미티드 | Egfr 및/또는 vegf에 대해 결합 특이성이 있는리간드 및 그의 사용 방법 |
GB0724331D0 (en) | 2007-12-13 | 2008-01-23 | Domantis Ltd | Compositions for pulmonary delivery |
KR20100018040A (ko) * | 2007-06-06 | 2010-02-16 | 도만티스 리미티드 | 프로테아제 내성 폴리펩티드를 선택하는 방법 |
US7868885B2 (en) | 2007-06-22 | 2011-01-11 | Microsoft Corporation | Direct manipulation of subdivision surfaces using a graphics processing unit |
EA201270174A1 (ru) * | 2009-07-16 | 2012-07-30 | Глэксо Груп Лимитед | Отдельные связывающиеся вариабельные домены с улучшенными свойствами, направленные против сывороточного альбумина |
CA2768460A1 (en) * | 2009-07-16 | 2011-01-20 | Glaxo Group Limited | Antagonists, uses & methods for partially inhibiting tnfr1 |
TW201125877A (en) * | 2009-10-27 | 2011-08-01 | Glaxo Group Ltd | Stable anti-TNFR1 polypeptides, antibody variable domains & and antagonists |
-
2010
- 2010-02-17 JP JP2011550552A patent/JP2012517818A/ja active Pending
- 2010-02-17 WO PCT/EP2010/052005 patent/WO2010094720A2/en active Application Filing
- 2010-02-17 CA CA2750477A patent/CA2750477A1/en not_active Abandoned
- 2010-02-17 AU AU2010215479A patent/AU2010215479B2/en not_active Ceased
- 2010-02-17 US US13/202,349 patent/US20110301335A1/en not_active Abandoned
- 2010-02-17 EA EA201190116A patent/EA022925B1/ru not_active IP Right Cessation
- 2010-02-17 SG SG2011054459A patent/SG173173A1/en unknown
- 2010-02-17 KR KR1020117021824A patent/KR20110119806A/ko not_active Application Discontinuation
- 2010-02-17 EP EP10704151A patent/EP2398827A2/en not_active Withdrawn
- 2010-02-17 MX MX2011008799A patent/MX2011008799A/es not_active Application Discontinuation
- 2010-02-17 BR BRPI1008014A patent/BRPI1008014A2/pt not_active IP Right Cessation
- 2010-02-17 CN CN2010800173301A patent/CN102405236A/zh active Pending
-
2011
- 2011-07-29 ZA ZA2011/05627A patent/ZA201105627B/en unknown
- 2011-08-15 IL IL214648A patent/IL214648A0/en unknown
-
2015
- 2015-07-31 JP JP2015151376A patent/JP2016007218A/ja active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2012517818A5 (ja) | ||
JP2018108081A5 (ja) | ||
JP6475712B2 (ja) | サイトカインアンタゴニストの標的化 | |
JP2010530220A5 (ja) | ||
JP2009539349A5 (ja) | ||
JP2009511579A5 (ja) | ||
US9708402B2 (en) | Anti-BAFF-anti-IL-17 bispecific antibodies | |
JP2017500018A5 (ja) | ||
JP2017029157A5 (ja) | ||
JP2017523786A5 (ja) | ||
JP2009521909A5 (ja) | ||
JP2018521691A5 (ja) | ||
JP2011526792A5 (ja) | ||
JP2008501716A5 (ja) | ||
JP2008525033A5 (ja) | ||
JP2014534237A5 (ja) | ||
JP2017113019A5 (ja) | ||
JP2009518005A5 (ja) | ||
JP2014503209A5 (ja) | ||
JP2007536932A5 (ja) | ||
JP2014518883A5 (ja) | ||
JP2016539096A5 (ja) | ||
JP2011518857A5 (ja) | ||
JP2011520989A5 (ja) | ||
JP2019522961A5 (ja) |